Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis

Thu Feb 2 18:52:57 2023

(2022) Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis. Frontiers in pharmacology. p. 955050. ISSN 1663-9812 (Print) 1663-9812 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/36110536

Abstract

Introduction: Linezolid (LNZ) is an effective antibiotic to treat patients with multidrug-resistant tuberculosis (MDR-TB) treatment failure. M. tuberculosis strains resistant to isoniazid and rifampin are defined as MDR-TB. In recent years, resistance to LNZ among MDR-TB cases has been reported in several different countries. In this study, we performed a systematic review and meta-analysis to investigate the prevalence of LNZ resistance among MDR-TB isolates. Methods: The databases of Embase, PubMed/Medline, and Web of Science were searched systematically from January 2000 to April 2021. Statistical analyses were performed by using Comprehensive Meta-Analysis software. Heterogeneity was reported by using the t-squared statistic and Q-statistic. Begg's rank correlation in combination with the funnel plot were used to evaluate any possible publication bias. Results: In total, 25 studies were selected for meta-analysis from 14 different countries; the majority was from China (n = 5) and Turkey (n = 4). Moreover, 7,366 patients were infected with MDR M. tuberculosis. Among the study population, 98 patients were co-infected with HIV, and 18 patients with hepatitis C virus (HCV). Furthermore, 28 cases had diabetes, and139 cases were alcohol abuser. Overall, 4,956 MDR M. tuberculosis strains were isolated from TB patients. The pooled frequency of LNZ resistance among the clinical isolates of MDR M. tuberculosis was 4.2 (95). Begg's (p = 0.72) test showed no evidence of publication bias. Conclusion: LNZ resistance among MDR M. tuberculosis isolates is increasing. On the other hand, long-term treatment of MDR-TB cases with LNZ alone is associated with several adverse effects. Thus, it is recommended that newer anti-TB drugs, including bedaquiline and delamanid, in combination with linezolid could increase its effectiveness and decrease toxicities. However, more studies should be done in this field.

Item Type: Article
Creators:
CreatorsEmail
Azimi, T.UNSPECIFIED
Khoshnood, S.UNSPECIFIED
Asadi, A.UNSPECIFIED
Heidary, M.UNSPECIFIED
Mahmoudi, H.UNSPECIFIED
Kaviar, V. H.UNSPECIFIED
Hallajzadeh, M.UNSPECIFIED
Nasiri, M. J.UNSPECIFIED
Keywords: Mdr-tb Tb linezolid meta-analysis resistance tuberculosis commercial or financial relationships that could be construed as a potential conflict of interest.
Divisions:
Page Range: p. 955050
Journal or Publication Title: Frontiers in pharmacology
Journal Index: Pubmed
Volume: 13
Identification Number: https://doi.org/10.3389/fphar.2022.955050
ISSN: 1663-9812 (Print) 1663-9812 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4066

Actions (login required)

View Item View Item